| 霍安妮,周 娟,王春佟,吕 丹,樊和丽.培美曲塞联合长春瑞滨治疗复发转移性宫颈癌患者对疾病控制及预后随访研究[J].现代生物医学进展英文版,2021,(8):1511-1515. |
| 培美曲塞联合长春瑞滨治疗复发转移性宫颈癌患者对疾病控制及预后随访研究 |
| Pemetrexed Combined with Vinorelbine in the Treatment of Patients with Recurrent and Metastatic Cervical Cancer for Disease Control and Prognosis Follow-up Study |
| Received:October 28, 2020 Revised:November 23, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.08.024 |
| 中文关键词: 复发转移性宫颈癌 培美曲塞 长春瑞滨 疾病控制 生存率 毒副反应 |
| 英文关键词: Recurrent and metastatic cervical cancer Pemetrexed Vinorelbine Disease control Survival rate Side effects |
| 基金项目:国家自然科学基金项目(81273902) |
|
| Hits: 882 |
| Download times: 583 |
| 中文摘要: |
| 摘要 目的：探讨培美曲塞联合长春瑞滨治疗复发转移性宫颈癌对疾病控制及预后的影响。方法：选择2018年5月~2019年6月收治的100例复发转移性宫颈癌患者，按照随机数表法分观察组和对照组，每组50例。对照组采用紫杉醇联合顺铂化疗，观察组则采用培美曲塞联合长春瑞滨治疗。比较2组疾病控制效果，记录患者化疗前后Karnofsky评分变化，统计2组患者毒副反应及生存率、生存期。结果：观察组的疾病控制率为84.00%，明显高于对照组的62.00%，差异显著（P<0.05）；治疗后，2组患者的Karnofsky评分均升高，且观察组[（86.25±3.02）分]明显高于对照组[（81.15±3.11）分]，差异显著（P<0.05）； 2组患者胃肠道反应、骨髓抑制、血小板计数减少、恶心呕吐等毒副反应发生率比较，无明显差异（P>0.05）；观察组患者的1年生存率70.00%、2年生存率58.00%、3年生存率26.00%均高于对照组的50.00%、38.00%、10.00%，观察组的生存期[（18.12±3.21）月]长于对照组[（14.18±2.81）月]，差异显著（P<0.05）。结论：培美曲塞联合长春瑞滨治疗复发转移性宫颈癌效果显著，可有效提高患者的生存质量及生存率，延长生存期，毒副反应低，患者耐受性好，可在临床推广运用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of pemetrexed combined with vinorelbine in the treatment of recurrent and metastatic cervical cancer on disease control and prognosis. Methods: 100 patients with recurrent and metastatic cervical cancer admitted from May 2018 to June 2019 were selected and divided into observation group and control group according to the random number table method, with 50 cases in each group. The control group was treated with paclitaxel combined with cisplatin chemotherapy, and the observation group was treated with pemetrexed combined with vinorelbine. The disease control effects of the two groups were compared, the Karnofsky score changes before and after chemotherapy were recorded, and the toxicity, survival rate and survival period of the two groups were counted. Results: The disease control rate of the observation group was 84.00%, which was significantly higher than the 62.00% of the control group. The difference was significant (P<0.05). After treatment, the Karnofsky scores of the two groups increased, and the observation group [(86.25±3.02) Score] was significantly higher than that of the control group [(81.15±3.11) points], and the difference was significant (P<0.05); Comparison of the incidence of side effects such as gastrointestinal reactions, bone marrow suppression, platelet count reduction, nausea and vomiting in the two groups, no Significant difference (P>0.05); the 1-year survival rate of the observation group was 70.00%, the 2-year survival rate was 58.00%, and the 3-year survival rate 26.00% were higher than those of the control group, 50.00%, 38.00%, and 10.00%. The survival period [(18.12±3.21) months] was longer than that of the control group [(14.18±2.81) months], the difference was significant (P<0.05). Conclusion: Pemetrexed combined with vinorelbine has a significant effect in the treatment of recurrent and metastatic cervical cancer. It can effectively improve the quality of life and survival rate of patients, prolong survival, low toxic and side effects, and good patient tolerance. It can be used in clinical applications. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
